Business
MiNK Therapeutics Announces 77% Survival Rate in Intubated Patients with COVID-19 Respiratory Failure Treated with AgenT-797
No evidence of neurotoxicity or cytokine release syndromeEarly signals of tumor biomarker suppression and disease stabilization beyond 6 months in
About this update from Mink Therapeutics, Inc.
[{"type":"text","content":"No evidence of neurotoxicity or cytokine release syndromeEarly signals of tumor biomarker suppression and disease stabilization beyond 6 months in relapsed/refractory multiple myelomaiNKTs demonstrated potent tumor killing in solid tumor models NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced preliminary survival data from its phase 1 study of, agenT-797 (iNKT cell therapy) in intubated COVID-19 acute respiratory distress syndrome patients, and also presented new insights on its iNKT programs in cancer at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021). “The data from the study of iNKTs in patients with COVID-19 respiratory failure are compelling and show a much higher survival rate than we have seen in our community-based cohort of older, intubated patients,” said Dr. Terese Hammond, Director of Pulmonary Critical Care at Providence Saint John’s Health Care Center ICU. “Importantly, little has changed in respiratory failure management since 20001 so the use of iNKT therapies in critical care medicine could potentially be a game changer.” “Collectively, our SITC data highlight the disease modifying potential of agenT-797 in cancer and infections,” said Jennifer Buell, Ph.D., President and CEO of MiNK Therapeutics. “We are enthusiastic about these findings and plan to rapidly expand our clinical programs, including our solid tumor trial of agenT-797 in combination with checkpoint inhibitors which is now cleared by the FDA to start dosing.” MiNK data demonstrated: AgenT-797 in COVID-19 respiratory failure showed a 77% survival rate in older, ventilated patients compared to the national average approximating 20-30%.AgenT-797 demonstrated early signals of tumor biomarker suppression and disease stabilization beyond 6 months in relapsed/refractory multiple myeloma without lymphodepletion.MiNK has developed proprietary methods for the study of iNKTs, including a digital PCR-based methodology to track unmodified allogeneic iNKT cells in patients and a xenograft model for the study of agenT-797 to recapitulate human iNKT cell distribution and evaluate...